Abbott gets rights to Reata's Phase II bardoxolone; Reata reacquires rights
Reata Pharmaceuticals Inc. (developing oral anti-inflammatories) has licensed Abbott Laboratories Inc. exclusive rights outside the US and some Asian countries to develop and commercialize bardoxolone (RTA402), which is in late Phase II trials for chronic kidney disease (CKD).
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.